🚶‍♂️🚶‍♀️How many steps a day for better health? Meta-analysis of 57 studies 7,000 steps/day associated with ⬇️ risk of: 🩺 All-cause mortality ↓47% ❤️ CVD mortality ↓47% 🧠 Dementia ↓38% 😔 Depression ↓22% 🎗️ Cancer mortality ↓37% 🤕 Falls ↓28% thelancet.com/journals/lanpu…

Adult & Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study ➡️Still more to learn on trajectories of single antibody positivity… however stage 2 T1D and progression more defined in adults or children diabetesjournals.org/care/article-a…

Wow, the game has changed! #SURPASSCVOT meets its primary & secondary endpoints in first *head-to-head* CV outcomes trial! Tirzepatide (dual GLP1/GIP agonist) vs Dulaglutide (GLP-1RA) including 16% lower risk of all cause mortality! investor.lilly.com/news-releases/…

❗️Tirzepatide meets primary and secondary outcomes in its CVOT (SURPASS-CVOT)❗️ 🔹A first for CVOTs - comparing to dulaglutide (established benefit) 🔸Statistical analysis allows for comparison to putative placebo 🔹1ry outcome HR 0.92 p=0.086 🔸2ndry outcome HR 0.84 0=0.002

Muthu Vaduganathan GoggleDocs Brendon Neuen C. Michael Gibson MD Sek Kathiresan MD Ankeet S. Bhatt, MD, MBA Anu Lala-Trindade Shelley Zieroth Beverly G. Tchang, MD Javed Butler David J. Cohen, MD, MSc sciencedirect.com/science/articl… Link to baseline characteristics and background 😁😇

📉 What happens after stopping anti-obesity meds? Meta-analysis Significant weight regain begins 8 weeks after discontinuation Continuing through 20 weeks. 🔁 Regain most notable with GLP-1 RAs ⚠️ Need for long-term strategies beyond medication alone bmcmedicine.biomedcentral.com/articles/10.11…

📢 Obesity associated with risk of atrial fibrillation 🔍 10-year cohort of 392,000+ adults Obesity increased AF risk by 43%. ⚠️ Only ~27% of this was mediated by conditions like diabetes & hypertension 73% was a direct effect. 🧠 #Preventobesity dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

📊 GLP-1 & SGLT2 in T2D: Discontinuation, Reinitiation & Switching Swedish registry data 🔄 Discontinuation GLP-1 RA: 24% at 1 yr, 39% at 3 yrs SGLT2i: 28% at 1 yr, 46% at 3 yrs 🔎 Despite high discontinuation, 70–80% remained on therapy long term link.springer.com/article/10.100…

❗️ATTAIN-1 topline results announced ❗️ investor.lilly.com/news-releases/… 🔹almost 60% achieving 10% weight loss (we’ve moved beyond the 5% target now😁) with higher dose 🔸-12.4% change body weight with higher dose - rivals many injectables 🔹small molecule oral tablet - could open up

Oh look what has come up 🙂 11 years ago... Via The King's Fund Sarah Woolnough 'Integrated care #Diabetes" Before the national role NHS England Before the world of #T1Diabetes Before the battle for #Technology Portsmouth Hospitals University NHST Hampshire and IOW Healthcare NHS Foundation Trust working together across NHS Hampshire and Isle of Wight ...set up

Comprehensive review by Shivani Misra Ethnic diversity in precision medicine: a reality or an aspiration?

🧠💉 Potential neuroprotective & cerebrovascular benefits of GLP-1RAs, beyond glycaemic & weight control. 📉 Compared to other antidiabetic meds, semaglutide/tirzepatide users had: 🧠 ↓ Dementia risk ↓ Stroke risk ⚰️ ↓ All-cause mortality jamanetwork.com/journals/jaman…

🚶‍♂️ Benefits of fast walking Walking briskly ≥15 min/day cut all-cause mortality by ~20%, vs only ~4% for >3h/day slow walking Benefits were strongest for heart-related deaths & in those with chronic illness. #PublicHealth #Walking ajpmonline.org/article/S0749-…

📊 DAPA-MI Trial Randomised to dapagliflozin or placebo 📉 Key Results 🔻 New-onset T2DM risk ↓ Greatest benefit in BMI ≥30 + in those with prediabetes ✅Dapagliflozin may prevent T2DM & lower heart failure symptom burden post-MI Now off patent😜 ahajournals.org/doi/10.1161/JA…

🧠 Sleep & Health 📊 Study in 88,461 UK Biobank participants 🧬 Key Findings (6.8 years follow-up): 172 diseases linked to poor sleep 🧪 Inflammation markers mediated many links Sleep health = systemic health spj.science.org/doi/10.34133/h…

❗️Teplizumab approved by MHRAgovuk ❗️ Great news - esp after seeing all the hard work go into this firsthand! ➡️First ever immunotherapy in UK approved for T1D ➡️ delay the onset of Stage 3 T1D in adults & children 8yrs & older with Stage 2 T1D gov.uk/government/new…

And.. the next episode of 'Kar-Mic' 😀 "Musings with Misra" A chat with one of the brightest stars of the #Diabetes world Shivani Misra Chatting about leading ground-breaking research around '#T2D in the Young'; 'Precision Medicine', being a role model, and talking about the

‼️‼️Draft new NG28 is now out! ‼️‼️ We finally have better access To GLP1s! 🥳 ▶️now groups split into subsets (frailty/HF/EOT2D etc) ▶️talks about NOT stopping meds once A1c is good if not having hypos 🔗 nice.org.uk/guidance/gid-n…